Swiss drugmaker Novartis is acquiring U.S. biotech firm Avidity Biosciences for approximately $12 billion in cash, or $72 per share representing a 46% premium, to bolster its portfolio of treatments for rare muscle disorders. This strategic acquisition helps Novartis address impending patent expirations for blockbuster drugs and expand into areas with limited treatment options, leveraging Avidity's RNA therapeutic pipeline for neuromuscular diseases. As part of the deal, Avidity's early-stage precision cardiology programs will be spun off into a new publicly traded entity, Spinco, while the acquisition also reinforces Novartis's U.S. market presence and aligns with its recent M&A strategy.
Novartis (NVS) is set to acquire Avidity Biosciences (RNA) for $12 billion in cash, offering a 46% premium at $72 per share, signaling a strong strategic move. This acquisition aims to fortify Novartis's rare muscle disorder portfolio and mitigate revenue loss from impending patent expirations on blockbuster drugs such as Entresto and Cosentyx. The deal integrates Avidity's clinical-stage pipeline, including Del-zota for Duchenne muscular dystrophy and other RNA therapeutic candidates targeting neuromuscular disorders, with potential approvals by 2026. This aligns with Novartis's recent M&A strategy, exemplified by its acquisitions of Kate Therapeutics and Anthos Therapeutics, focusing on specialized therapies. A notable aspect of the transaction is the spin-off of Avidity's early-stage precision cardiology programs into a new publicly traded company, Spinco. This acquisition also strategically enhances Novartis's U.S. market presence, providing a hedge against potential pharmaceutical tariffs proposed by the Trump administration, which previously imposed tariffs on Swiss exports.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
